---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157390"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:46:12.786566+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Bezuclastinib SUMMIT trial beats all primary/secondary endpoints; NDA submission by end 2025

## Summary
- SUMMIT trial met primary endpoint: mean TSS reduction of 24.3 vs 15.4 placebo (p=0.0002); 8.91-point placebo-adjusted improvement.
- 87.4% of bezuclastinib patients had ≥50% reduction in serum tryptase vs 0% placebo (p<0.0001).
- NDA submission to FDA expected by end of 2025; plan to present full data at medical meeting.
- Raised ~$230M gross via offering of 22.2M shares at $9 (plus underwriter option fully exercised).
- Cash balance ~$237M as of June 30, 2025; access to up to $350M via debt facility.

## SEC filing metadata
- accession: 0001193125-25-157390
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312525157390/0001193125-25-157390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312525157390/d92808d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157390
- JSON: https://secwatch.observer/filing/0001193125-25-157390.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.